Objective To analyze the prognosis of patients with unruptured cerebral arteriovenous malformation (CAVM) with epilepsy treated with endovascular embolization.Methods A total of 49 patients with CAVM with epilepsy who were admitted to the hospital from March 2013 to June 2017 and met the diagnostic criteria were enrolled and analyzed for their improvements in the clinical symptoms and Quality of Life in Epilepsy-31 (QOLIE-31) after endovascular embolization.Results After treatment with endovascular embolization, the scores on all items (except for drug effects) of QOLIE-31 were significantly increased (P<0.05); the numbers of patients with Spetzler-Martin grade I-Ⅱ and Engel grade I-Ⅱ disease were significantly increased (P<0.05); Spetzler-Martin grade I-Ⅱ cases had significantly higher quality of life (QOL) scores than Spetzler-Martin grade Ⅲ-V cases (76.04±18.33 vs 65.65±16.76, P<0.05), and Engel grade I-Ⅱ cases had significantly higher QOL scores than Engel grade Ⅲ-V cases (75.25±17.78 vs 66.23±13.22, P<0.05); the total QOL score was significantly higher in patients with an endovascular embolization rate of >80% than in those with an endovascular embolization rate of <80% (78.37±18.87 vs 64.16±16.92, P<0.05); the number of patients with severe headache was significantly reduced (P<0.01); the National Institutes of Health Stroke Scale and Modified Rankin Scale scores were significantly decreased (P<0.05), and the QOL score of headache symptoms was significantly increased (P<0.05).Conclusions Endovascular embolization can significantly improve headache symptoms, epileptic seizures, and neurological deficits in patients with unruptured CAVM with epilepsy, indicating that increasing the rate of endovascular embolization can improve patients' QOL.